FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Real-time Boerse Frankfurt Warrants 07:54:13 2024-05-23 EDT | ||
| 6.36 EUR | +0.47% |
|
| Current month | +7.29% | ||
| 1 month | -2.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 6.36 | +0.47% |
| 24-05-22 | 6.33 | +0.16% |
| 24-05-21 | 6.32 | -2.62% |
| 24-05-20 | 6.49 | +1.88% |
| 24-05-17 | 6.37 | -1.09% |
Real-time Boerse Frankfurt Warrants
Last update May 23, 2024 at 07:54 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SF5W82 |
| ISIN | DE000SF5W825 |
| Date issued | 2021-10-21 |
| Strike | 66.91 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.61 € |
|---|---|
| Lowest since issue | 5.64 € |
| Spread | 0.06 € |
| Spread % | 0.94% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.8
USD
Average target price
82.93
USD
Spread / Average Target
+22.31%
- Stock Market
- Certificates
- Certificat
